File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Delayed low-level calcineurin inhibition promotes allospecific tolerance induction by posttransplantation donor leukocyte infusion

TitleDelayed low-level calcineurin inhibition promotes allospecific tolerance induction by posttransplantation donor leukocyte infusion
Authors
Issue Date2002
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.com
Citation
Transplantation, 2002, v. 73 n. 8, p. 1325-1332 How to Cite?
AbstractBackground. Donor lymphocytes infused after organ transplantation can have strong immunoregulatory effects. Application of such protocols for transplant tolerance induction in a clinical setting will, however, require combination of specific immunomodulatory strategies with nonspecific immunosuppressive medication for safety reasons. The aim of this study was to analyze the effects of immunosuppressive treatment on tolerance induction protocols by posttransplantation donor lymphocyte infusion. Methods. The interaction of postoperative donor leukocyte infusion with different types, dosage, and timing of immunosuppressive drugs were studied in a rat model of heart transplantation. Results. Tolerance could be achieved if donor cell infusion was combined with delayed, but not immediate, low-dose cyclosporine treatment, and this was associated with activation and apoptosis of host lymphocytes. In contrast, combinations with an antibody against the interleukin 2 receptor led to long-term graft survival but severe chronic rejection, and combinations with high-dose cyclosporine or sirolimus led to acute rejection. Conclusions. Postoperative donor leukocyte infusion is a potential way for tolerance induction, but the type, dose, and timing of medication are highly critical for its efficacy.
Persistent Identifierhttp://hdl.handle.net/10722/172815
ISSN
2015 Impact Factor: 3.69
2015 SCImago Journal Rankings: 1.699
References

 

DC FieldValueLanguage
dc.contributor.authorTsui, TYen_US
dc.contributor.authorJäger, MDen_US
dc.contributor.authorDeiwick, Aen_US
dc.contributor.authorAselmann, Hen_US
dc.contributor.authorNeipp, Men_US
dc.contributor.authorFan, STen_US
dc.contributor.authorSchlitt, HJen_US
dc.date.accessioned2012-10-30T06:25:04Z-
dc.date.available2012-10-30T06:25:04Z-
dc.date.issued2002en_US
dc.identifier.citationTransplantation, 2002, v. 73 n. 8, p. 1325-1332en_US
dc.identifier.issn0041-1337en_US
dc.identifier.urihttp://hdl.handle.net/10722/172815-
dc.description.abstractBackground. Donor lymphocytes infused after organ transplantation can have strong immunoregulatory effects. Application of such protocols for transplant tolerance induction in a clinical setting will, however, require combination of specific immunomodulatory strategies with nonspecific immunosuppressive medication for safety reasons. The aim of this study was to analyze the effects of immunosuppressive treatment on tolerance induction protocols by posttransplantation donor lymphocyte infusion. Methods. The interaction of postoperative donor leukocyte infusion with different types, dosage, and timing of immunosuppressive drugs were studied in a rat model of heart transplantation. Results. Tolerance could be achieved if donor cell infusion was combined with delayed, but not immediate, low-dose cyclosporine treatment, and this was associated with activation and apoptosis of host lymphocytes. In contrast, combinations with an antibody against the interleukin 2 receptor led to long-term graft survival but severe chronic rejection, and combinations with high-dose cyclosporine or sirolimus led to acute rejection. Conclusions. Postoperative donor leukocyte infusion is a potential way for tolerance induction, but the type, dose, and timing of medication are highly critical for its efficacy.en_US
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.comen_US
dc.relation.ispartofTransplantationen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntibodies - Therapeutic Useen_US
dc.subject.meshCalcineurin - Genetics - Physiologyen_US
dc.subject.meshCyclosporine - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshGraft Rejection - Immunologyen_US
dc.subject.meshGraft Survival - Immunologyen_US
dc.subject.meshHeart Transplantation - Immunology - Pathologyen_US
dc.subject.meshImmunosuppression - Methodsen_US
dc.subject.meshImmunosuppressive Agents - Therapeutic Useen_US
dc.subject.meshLeukocyte Transfusionen_US
dc.subject.meshLymphocyte Transfusionen_US
dc.subject.meshMaleen_US
dc.subject.meshRatsen_US
dc.subject.meshRats, Inbred Bnen_US
dc.subject.meshRats, Inbred Lewen_US
dc.subject.meshReceptors, Interleukin-2 - Immunologyen_US
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen_US
dc.subject.meshSirolimus - Therapeutic Useen_US
dc.subject.meshSpleen - Immunologyen_US
dc.subject.meshTransplantation, Homologous - Immunologyen_US
dc.titleDelayed low-level calcineurin inhibition promotes allospecific tolerance induction by posttransplantation donor leukocyte infusionen_US
dc.typeArticleen_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid11981429-
dc.identifier.scopuseid_2-s2.0-0037181684en_US
dc.identifier.hkuros68982-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0037181684&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume73en_US
dc.identifier.issue8en_US
dc.identifier.spage1325en_US
dc.identifier.epage1332en_US
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridTsui, TY=7006622455en_US
dc.identifier.scopusauthoridJäger, MD=7103272911en_US
dc.identifier.scopusauthoridDeiwick, A=6602705951en_US
dc.identifier.scopusauthoridAselmann, H=6603094705en_US
dc.identifier.scopusauthoridNeipp, M=6701482784en_US
dc.identifier.scopusauthoridFan, ST=7402678224en_US
dc.identifier.scopusauthoridSchlitt, HJ=7005572464en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats